Tissue-agnostic cancer drug
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.[1][2][3] Tissue-agnostic drugs include Pembrolizumab (Keytruda) and Larotrectinib (Vitrakvi).[2] [4]
History[edit | edit source]
Petrolizumab was approved by the US Food and Drug Administration In May 2017.[5]
Larotrectinib was approved by the FDA in November, 2018.[5]
Loxo-292 received priority review in September 2018.[5]
Other drugs under development include Entrectinib, BLU-667, Loxo-195 and Anti-ERBB3 antibody.[5]
References[edit | edit source]
Tissue-agnostic cancer drug Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD